Recently, PFKFB3 has been shown to be a promising target, not only due to its crucial involvement in glycolysis, but also because of its ability to induce tumor vessel normalization and to lead to drug sensitization [5,6,39,40]. The gene discussed is PFKFB3; the disease is neoplasm.